MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

AVEO Pharmaceuticals Company Profile (NASDAQ:AVEO)

Consensus Ratings for AVEO Pharmaceuticals (NASDAQ:AVEO) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $2.35 (150.00% upside)

Analysts' Ratings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Show:
DateFirmActionRatingPrice TargetActions
6/20/2016FBR & CoReiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
6/16/2016Piper Jaffray Cos.Reiterated RatingBuyView Rating Details  Tweet This Rating  Share This Rating on StockTwits
3/9/2015Royal Bank Of CanadaUpgradeUnderperform -> Sector Perform$2.00 -> $3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 7/1/2014 forward)
Earnings History for AVEO Pharmaceuticals (NASDAQ:AVEO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/10/2016Q1($0.12)($0.13)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/15/2016Q415($0.04)($0.11)$3.60 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/9/2015Q315($0.09)$0.14ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q2($0.16)($0.10)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2015Q115($0.25)($0.21)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/6/2015Q314($0.28)($0.27)ViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2014($0.23)($0.28)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/11/2014Q214($0.44)($0.35)$1.75 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/7/2014($0.40)($0.12)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.33)($0.32)$0.14 million$0.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/4/2013Q313($0.47)($0.47)$0.23 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/1/2013Q213($0.56)($0.62)$4.30 million$0.32 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
4/29/2013Q1 2013($0.72)($0.69)$2.52 million$0.32 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/13/2013Q4 2012($0.77)($0.49)$14.49 million$15.53 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
10/30/2012Q312($0.87)($0.69)$6.57 million$1.02 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/2/2012($0.82)($0.68)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/3/2012($0.78)($0.77)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
2/14/2012($0.64)($0.58)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/2/2011($0.46)($0.55)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
7/28/2011($0.80)($0.16)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for AVEO Pharmaceuticals (NASDAQ:AVEO)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.13)($0.13)($0.13)
Q2 20161($0.15)($0.15)($0.15)
Q3 20161($0.18)($0.18)($0.18)
Q4 20161($0.21)($0.21)($0.21)
(Data provided by Zacks Investment Research)
Dividend History for AVEO Pharmaceuticals (NASDAQ:AVEO)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for AVEO Pharmaceuticals (NASDAQ:AVEO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
1/16/2015Matthew D DallasVPSell3,075$0.82$2,521.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/7/2015Michael P BaileyCEOSell4,484$0.80$3,587.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
1/30/2014Joseph VittiglioSVPSell5,430$1.64$8,905.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/14/2013David Brannon JohnstonCFOSell1,061$7.34$7,787.74View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/7/2013Henri A TermeerDirectorBuy55,499$6.73$373,508.27View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Ngoc Tuan HaCEOBuy75,000$6.65$498,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/13/2012Robert C YoungDirectorBuy2,371$6.78$16,075.38View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/3/2012Robert C YoungDirectorBuy1,250$6.41$8,012.50View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/13/2012David Brannon JohnstonCFOSell1,386$10.60$14,691.60View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/8/2012Robert C YoungDirectorBuy1,000$8.63$8,630.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for AVEO Pharmaceuticals (NASDAQ:AVEO)
DateHeadline
06/27/16 07:23 AMNext Weeks Broker Price Targets For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Fiscal Standard
06/25/16 02:39 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Covered 30.26% of Their Shorts - Engelwood Daily
06/23/16 04:12 PMNew Broker Ratings For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - FTSE News
06/23/16 10:30 AMSmall-Cell Lung Cancer Pipeline Market 2016 Global Company Profiles Research
06/22/16 07:27 AMReport delivers insight into the small-cell lung cancer therapeutics drugs and companies pipeline review
06/17/16 10:36 AMAVEO PHARMACEUTICALS INC : Termination of a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)
06/16/16 07:02 AMBRIEF-Aveo Pharmaceuticals says sale of 37.1 mln shares by stockholders - Reuters
06/15/16 04:24 PMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Termination of a Material Definitive Agreement, Regulation FD Disclosure -
06/15/16 06:29 AMAVEO to Present at the 2016 JMP Securities Life Science Conference - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jun. 15, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that Michael Needle, M.D., Chief Medical Officer, will present at the 2016 JMP Securities Life Sciences Conference ...
06/08/16 09:01 PMAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Updated Price Targets - FTSE News
06/08/16 03:05 PMWill AVEO Pharmaceuticals (AVEO) Continue to Surge Higher? - Nasdaq
06/08/16 04:52 AMWill AVEO Pharmaceuticals (AVEO) Continue to Surge Higher? -
06/07/16 10:52 AMHead and neck cancer squamous cell carcinoma pipeline market review 2016 made available by top research firm
06/03/16 02:10 PMETF’s with exposure to AVEO Pharmaceuticals, Inc. : June 3, 2016 -
06/02/16 11:23 AMLatest Price movements of Stocks: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) , Stryker Corporation (NYSE:SYK) - Street Updates - Latest Price movements of Stocks: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) , Stryker Corporation (NYSE:SYK)Street UpdatesOn 6/1/2016, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) highlighted upward shift of +14.00% or +0.13 points to $1.09. The company traded a volume of 1.38 million shares over average volume of 239.87 thousand shares. Trailing twelve month period, the ...and more »
06/02/16 11:23 AMAVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)'s AGM: This Is What Shareholders Need To Know - Scibility Media - AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO)'s AGM: This Is What Shareholders Need To KnowScibility MediaAt its recent annual shareholder meeting, AVEO Pharmaceuticals, Inc. (NASDAQ: AVEO) got its shareholders to approve the nominees to its board of directors. The company also secured ratification of Ernst & Young LLP as its independent public accountant.
06/02/16 11:23 AMWhat should one expect from? - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), First Horizon National Corporation ... - Beacon Chronicle - What should one expect from? - AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), First Horizon National Corporation ...Beacon ChronicleThe Previous Year EPS of this Quarter is -$0.1. AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) currently has High Price Target of $3. The Low and Mean Price Targets are $1.7 and $2.35 respectively. These price targets are a consensus analysis of 2 brokers.and more »
06/01/16 02:45 PMBroker Watchlist: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Share Trading News - Broker Watchlist: AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Share Trading News05/19/2016 – Piper Jaffray began new coverage on AVEO Pharmaceuticals, Inc. giving the company a “overweight” rating. They now have a USD 1.7 price target on the stock. 03/30/2016 – FBR Capital Markets began new coverage on AVEO Pharmaceuticals ...AVEO Pharmaceuticals Shares Jump 15% as Growth Equity Opportunities Fund Discloses 29.6% Stake (NASDAQ ...Sonoran Weekly Reviewall 2 news articles »
06/01/16 02:45 PMStocks on the Move: Galena Biopharma Inc (NASDAQ:GALE), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Viking ... - The Point Review - The Point ReviewStocks on the Move: Galena Biopharma Inc (NASDAQ:GALE), AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), Viking ...The Point ReviewShares of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) rose 12.64% to $1.07 at 11:27 AM EDT. The stock exchanged hands of 856,993 shares recently versus average trading capacity of 166,650 shares. However recently the stock touch highest trading ...and more »
05/31/16 02:57 PMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
05/28/16 01:18 PMAveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Increased By 58.72% Their Shorts - Wall Street Hints and News - Aveo Pharmaceuticals Incorporated (NASDAQ:AVEO) Sellers Increased By 58.72% Their ShortsWall Street Hints and NewsAVEO Pharmaceuticals, Inc. is a biopharmaceutical company. The company has a market cap of $53.67 million. The Company's platform delivers insights into cancer and related disease. It currently has negative earnings. The Company's product candidates ...and more »
05/26/16 01:21 PMBRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell ... - Reuters - BRIEF-Aveo Pharmaceuticals announces dosing of first patient in Phase 3 tivo-3 study of tivozanib in renal cell ...ReutersMay 26 Aveo Pharmaceuticals Inc. * Announces dosing of first patient in pivotal Phase 3 tivo 3 study of tivozanib in renal cell carcinoma. * Top line readout of study is currently projected for Q1 of 2018 Source text for Eikon: Further company coverage ...
05/26/16 01:21 PMPiper Jaffray Initiates Coverage on AVEO Pharmaceuticals to Overweight - Trade Calls - Piper Jaffray Initiates Coverage on AVEO Pharmaceuticals to OverweightTrade CallsIn a different note, FBR Capital said it Initiates Coverage on AVEO Pharmaceuticals, according to a research note issued on Mar 30, 2016. The shares have been rated 'Outperform' by the firm. AVEO Pharmaceuticals (AVEO) made into the market gainers list ...and more »
05/26/16 01:21 PMCompany Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Announces Dosing of First Patient in the Pivotal ... - Smarter Analyst - Company Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Announces Dosing of First Patient in the Pivotal ...Smarter AnalystAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that the first patient has been dosed in the Company's pivotal TIVO-3 trial, a randomized, controlled, multi-center, open-label study to compare tivozanib to sorafenib in subjects with refractory ...and more »
05/26/16 10:13 AMAVEO Pharmaceuticals, Inc. :AVEO-US: Earnings Analysis: Q1, 2016 By the Numbers : May 26, 2016 -
05/26/16 06:17 AMAVEO Announces Dosing of First Patient in the Pivotal Phase 3 TIVO-3 Study of Tivozanib in Renal Cell Carcinoma - [at noodls] - http://www.businesswire.com/news/home/20160526005388/en/ The Phase 3 trial is expected to enroll approximately 322 patients with recurrent or metastatic RCC who have failed at least two prior regimens, ...
05/24/16 11:52 AMTrending Tickers: AVEO Pharmaceuticals(NASDAQ:AVEO), Argos Therapeutics(NASDAQ:ARGS), Express Scripts ... - KC Register - Trending Tickers: AVEO Pharmaceuticals(NASDAQ:AVEO), Argos Therapeutics(NASDAQ:ARGS), Express Scripts ...KC RegisterOn May 18, AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that it has closed its previously announced private placement of 17,642,482 units, consisting of one share of common stock and a warrant to purchase one share of common stock, at a ...
05/22/16 12:55 PMAlpha One Assigns Impact Score Of 0 To AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Investor Newswire - Alpha One Assigns Impact Score Of 0 To AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Investor NewswireAlpha One analyzed the various web articles published on AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO), and thereafter it gave company a daily sentiment score of 0. The entity designs algorithm based assessment to known stock sentiment on stock after ...and more »
05/20/16 11:38 AMRecent research: 2015 H2 neck cancer pipeline market analysis - Inc. , AstraZeneca Plc , ATLAB Pharma SAS , AVEO Pharmaceuticals, Inc. , Bayer AG , Bexion Pharmaceuticals, LLC. , BIND Therapeutics, Inc. , Bio-Path Holdings, Inc. , BioDiem Ltd , Bionovis SA , Biotest AG , Boehringer Ingelheim GmbH , Boston Biomedical ...
05/19/16 12:04 PMAVEO PHARMACEUTICALS INC Financials -
05/19/16 05:36 AMCoverage initiated on AVEO Oncology by Piper Jaffray -
05/18/16 12:01 PMBRIEF-Aveo Pharmaceuticals announces closing of private placement and amended term loan - Reuters - BRIEF-Aveo Pharmaceuticals announces closing of private placement and amended term loanReutersMay 18 Aveo Pharmaceuticals Inc. * Announces closing of private placement and amended term loan to fund pivotal Tivo 3 trial and combination PD-1 trial of tivozanib in renal cell cancer. * Entered into an amendment to its 2010 loan and security ...
05/18/16 06:42 AMAVEO Announces Closing of Private Placement and Amended Term Loan to Fund Pivotal TIVO-3 Trial and Combination PD-1 Trial of Tivozanib in Renal Cell Cancer - [at noodls] - Private Placement Provides Gross Proceeds of Approximately $17 Million; Amended Term Loan to Provide up to $10 Million in Funding CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 18, 2016-- AVEO Oncology (NASDAQ:AVEO) ...
05/18/16 06:15 AMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Creation of a Direct Financial Obligation or an Obligation under an Off- -
05/16/16 01:49 PMAfter Last Week What Do Analysts Think Of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Share Trading News - After Last Week What Do Analysts Think Of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Share Trading News03/09/2015 – AVEO Pharmaceuticals, Inc. was upgraded to “sector perform” by analysts at RBC Capital. They now have a USD 3 price target on the stock. The share price of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was up +5.95% during the last trading ...
05/14/16 05:36 AMAVEO Pharmaceuticals : Announces $17 Million Private Placement - 05/11 AVEO PHARMACEUTICALS: Reports First Quarter 2016 Financial Results and Provides.. 05/11 AVEO PHARMACEUTICALS INC: Results of Operations and Financial Condition, Financ..
05/13/16 08:58 AMAVEO Announces $17 Million Private Placement - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 13, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it entered into a securities purchase agreement for a private placement with a select group of qualified ...
05/13/16 08:10 AMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Creation of a Direct Financi -
05/13/16 05:45 AMAVEO Pharmaceuticals, Inc. (AVEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPS - Washington News Wire - Washington News WireAVEO Pharmaceuticals, Inc. (AVEO) Releases Quarterly Earnings Results, Misses Expectations By $0.01 EPSWashington News WireAVEO Pharmaceuticals logo AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced its quarterly earnings results on Tuesday. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, missing the Thomson Reuters' consensus ...Stock Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results and ...Smarter AnalystAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) Basic Consolidated EPS At $-0.2693Stocks DailyUpgrades And Downgrades For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Risers & FallersZacks.comall 6 news articles »
05/11/16 09:19 AMAVEO Q1 Loss In Line with Expectation, Tivozanib in Focus -
05/11/16 05:16 AMBRIEF-Aveo Pharmaceuticals Q1 loss per share $0.13 - Reuters - ReutersBRIEF-Aveo Pharmaceuticals Q1 loss per share $0.13ReutersMay 10 Aveo Pharmaceuticals Inc. * Q1 loss per share $0.13. * Says believe that its cash resources would allow company to fund its current operations into Q4 of 2017 Source text for Eikon: Further company coverage: (Bengaluru Newsroom: ...
05/11/16 05:16 AMStock Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results and ... - Smarter Analyst - Stock Update (NASDAQ:AVEO): AVEO Pharmaceuticals, Inc. Reports First Quarter 2016 Financial Results and ...Smarter Analyst“We achieved several important goals in the first quarter critical to advancing the corporate strategy we outlined early in 2015. This includes the submission and validation of an MAA filing in Europe for tivozanib in front-line RCC by our partner EUSA ...and more »
05/11/16 05:07 AMAVEO PHARMACEUTICALS INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and -
05/10/16 03:18 PMAVEO Oncology Reports First Quarter 2016 Financial Results and Provides Business Update - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 10, 2016-- AVEO Oncology (NASDAQ:AVEO) today reported financial results for the first quarter ended March 31, 2016. ... This is an abstract of the original noodl. ...
05/10/16 03:13 PMAVEO reports 1Q loss -
05/10/16 03:04 PMAVEO PHARMACEUTICALS INC Files SEC form 10-Q, Quarterly Report -
05/10/16 05:37 AMHot Stocks: Avalanche Biotechnologies, Inc. (NASDAQ:AAVL), AVEO Pharmaceuticals (NASDAQ:AVEO), Tractor ... - KC Register - Hot Stocks: Avalanche Biotechnologies, Inc. (NASDAQ:AAVL), AVEO Pharmaceuticals (NASDAQ:AVEO), Tractor ...KC RegisterAVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) covering composition of matter claims for AV-353, the Company's potent inhibitory antibody ...and more »
05/02/16 06:10 AMAVEO Announces Filing of Provisional Patent Applications for AV-353, a Notch 3-Specific Inhibitor Antibody for PAH - [at noodls] - CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 2, 2016-- AVEO Oncology (NASDAQ:AVEO) today announced that it has filed provisional patent applications with the United States Patent and Trademark Office (USPTO) ...
05/02/16 06:00 AM7:00 am AVEO Oncology files provisional patent applications for AV-353, a notch 3-specific inhibitor antibody for PAH -
05/02/16 05:27 AMBroker Roundup For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) - Share Trading News - Broker Roundup For AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO)Share Trading NewsThe share price of AVEO Pharmaceuticals, Inc. (NASDAQ:AVEO) was down -3.63% during the last trading session, with a day high of 0.98. 323945 shares were traded on AVEO Pharmaceuticals, Inc.'s last session. The stock's 50 day moving average is 0.98 ...
About AVEO Pharmaceuticals

AVEO Pharmaceuticals logoAVEO Pharmaceuticals, Inc. (AVEO) is a biopharmaceutical company. The Company's platform has delivered insights into cancer and related disease. The Company's Human Response Platform (HRP) provides insights into cancer and related disease biology and is leveraged in the discovery and clinical development of its therapeutic candidates. The Company's product candidates include AV203, Ficlatuzumab, Tivozanib and AV380. AV203 inhibits the activity of the ErbB3 receptor and its preclinical studies suggest that neuregulin1 (NRG1). Ficlatuzumab is a Hepatocyte Growth Factor (HGF) inhibitory antibody. AV380 is for treatment of cachexia. Tivozanib is a potent selective long halflife vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI).

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: Biotechnology
  • Exchange: NASDAQ
  • Symbol: AVEO
  • CUSIP: 05358810
Key Metrics:
  • Previous Close: $0.94
  • 50 Day Moving Average: $0.96
  • 200 Day Moving Average: $0.99
  • P/E Ratio: N/A
  • P/E Growth: 0.00
  • Market Cap: $54.69M
  • Current Quarter EPS Consensus Estimate: $-0.51 EPS
Additional Links:
AVEO Pharmaceuticals (NASDAQ:AVEO) Chart for Friday, July, 1, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha